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March 3, 2009:812–6ith PES during mean follow-up periods ranging from 9 to 37
onths in a broad population (4). Our results demonstrate that the
enefits of SES can be extrapolated to diabetic patients.
In this study, there was no difference in the incidence of death
nd MI between SES and PES group. These findings are consis-
ent with a network meta-analysis of 38 trials showing that SES,
ES, and BMS were of comparative efficacy in risks of death, or
he combined end point of death or MI, in both diabetics and
ondiabetic patients for up to 4 years (5). In previous 2-year
ollow-up studies (2,3), the death (8.3% to 13.3% for SES and
0.8% to 11.5% for PES) and MI rate (1.9% to 5.1% for SES and
.4% to 6.5% for PES) were greater than in our study. This finding
ay be partly explained by the inclusion of high-risk populations and
ifferent duration of clopidogrel use compared with our study. The
onger administration of clopidogrel (9 months) after DES or BMS
educed death or MI in diabetic patients (6). In present study,
ajority of the patients took clopidogrel for9months (81% of study
opulation) with no significant difference in the duration of clopi-
ogrel use between SES and PES patients (491 377 days vs. 567
93 days, p 0.081). Optimal duration of clopidogrel use after DES
mplantation in diabetic patients should be determined in the future.
Recently published data reported that late stent thrombosis
ccurred steadily, with a constant rate of 0.6% per year, for up to
years after DES implantation. The 2-year incidence of stent
hrombosis in diabetic patients in previous studies was 2.8% to
.4% of SES patients and 2.4% to 2.6% of PES patients (2,3). In
ur study, none of the PES patients and only 2 SES patients (2 of
00, 1.0%) suffered from stent thrombosis (1 acute, 1 very late).
his discrepancy in the incidence of stent thrombosis may have
esulted from the differences in study design, inclusion criteria,
efinition of stent thrombosis, and duration of clopidogrel use.
In conclusion, SES implantation significantly reduced 2-year
isks of TLR and MACE compared with PES implantation in
iabetic patients. The use of SES with a larger post-procedural
inimal lumen diameter improved the 2-year clinical outcomes in
iabetic patients. Late stent thrombosis occurred only in 1 patient
0.25% of overall study population) during 2-year follow-up with
rolonged use of clopidogrel, which suggests that extended use of
lopidogrel after DES implantation in diabetic patients may be
eneficial to reduce long-term adverse clinical outcomes.
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nderson-Fabry Cardiomyopathy
e read with interest the article by Kounas et al. (1), in which theyiscriminating Anderson-Fabry disease from familial hypertrophic
ardiomyopathy compared with our findings previously published
n the Journal (2).
The definition of specificity and sensitivity usually implies
he identification of true and false positives as well as true and
alse negatives according to a diagnostic gold standard. In the
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March 3, 2009:812–6ettings of Anderson-Fabry cardiomyopathy, the gold standard
o define the presence of cardiac involvement is represented by
ndomyocardial biopsy demonstrating glycosphingolipid accu-
ulation in cardiac tissues. This finding is particularly true in
emale patients with borderline or mild left ventricular hyper-
rophy: in these patients, cardiac involvement can be absent in
ost cases (3), and cardiac wall thickening may be the result of
oncomitant hypertension often caused by initial renal involve-
ent. Accordingly, in our study, we evaluated the specificity
nd sensitivity of the binary sign in patients with Fabry disease
nd biopsy-proven cardiac involvement. On the contrary, in the
mall population described by Kounas et al. (1), no clear
emonstration of cardiac involvement is provided in the 5 (36%)
emale patients and in the 5 (36%) male patients with maximum
all thickness 15 mm included in the analysis to calculate
pecificity and sensitivity of the binary sign. Despite these
ethodological limitations, the overall specificity of the echo-
ardiographic sign remained 79% with a positive predictive
alue (calculated from the published data) of 63%. From these
onsiderations it emerges that, whatever its real specificity and
ensitivity, both studies identify the binary sign as a useful
dditional feature to search for during echocardiographic eval-
ation of patients with unexplained cardiac wall thickening. In
articular, it probably remains more sensitive and specific than
ther echocardiographic features, including concentric hyper-
rophy, right ventricular involvement, absence of outflow ob-
truction, and valve leaflet thickening, which usually are con-
idered in the differential diagnosis. On this basis, in our study
e suggested that binary appearance should be regarded not as
n infallible diagnostic hallmark but rather as a first filter to
ocus the enzymatic and genetic tests in a more selected
opulation in the settings of screening studies as well as of daily
chocardiography laboratory activity. In fact, we would like to
mphasize that the screening of large populations may be
xpensive and therefore available only in selected referral
enters, thus potentially retarding the proper diagnosis and
reatment. With this regard there is growing evidence (4) that
arly administration of enzyme replacement therapy is associ-
ted with better long-term results in terms of both cardiac and
ystemic symptoms improvement; thus, the early identification
nd treatment of this rare but potentially treatable cardiomy-
pathy is urgent.
Therefore, we believe that, even if obtained by adjusting image
uality and gain settings, the binary sign should be included among
he echocardiographic features, leading to a differential diagnosis
etween Anderson-Fabry cardiomyopathy and other forms of left
entricular hypertrophy.
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e thank Drs. Pieroni and Crea for their comments on our recent
aper (1). Our study was originally conceived as a response to an
rticle by one of the authors suggesting that the presence of a
inary endocardial appearance on 2-dimensional echocardiography
s 100% specific for the diagnosis of Anderson-Fabry disease
AFD) (2). Because our clinical experience suggested that the sign
as unreliable, we set out to prospectively test their findings in a
mall, blinded study of patients with genetically proven AFD. The
esults confirmed our clinical impression that the sign is not
pecific and that it is poorly reproducible.
Drs. Pieroni and Crea argue that a weakness of our paper (1)
s the lack of endomyocardial biopsy data to confirm the
resence of cardiac involvement. This argument is spurious for
number of reasons. Although it could be argued that endo-
yocardial biopsy is necessary for proving the presence of
ardiac involvement, it is not the gold standard for the diagnosis
f Anderson-Fabry disease, which requires the demonstration
f mutation in the gene encoding alpha-galactosidase A. Sec-
nd, most evidence suggests that glycosphingolipid accumula-
ion is present from a very early age (3), whereas clinical
vidence of organ involvement occurs much later (4). One can
ssume, therefore, that most adult patients presenting with
igns and symptoms of AFD will have histological evidence of
ardiac involvement, making the need for routine cardiac biopsy
n patients with biochemically and genetically proven AFD
nnecessary. Finally, knowledge of the histology does not
mprove the ability of the binary sign to reliably distinguish
atients with sarcomeric protein gene mutations from AFD,
rrespective of the degree of hypertrophy.
Drs. Pieroni and Crea suggest that the lack of biopsy data is a
articular problem in female patients because hypertrophy is rare in
omen with AFD and, when present, might be the result of
ypertension caused by renal involvement. These comments are
ot supported by data from a large international registry of patients
ith AFD that has shown that hypertrophy is common and severe
enal involvement rare in female patients (4).
In conclusion, we disagree strongly with Drs. Pieroni and Crea’s
uggestion that the binary sign could be used as a “first filter” in
creening large unselected populations with left ventricular hyper-
rophy before moving to dedicated genetic and enzymatic tests.
creening tests should be reproducible and highly specific to avoid
xclusion of false-negative cases from further diagnostic testing. In
ur experience, reliance on the binary sign would result in a
ubstantial number of misdiagnoses.
